Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1b study which will be conducted in two parts: part A is the
dose escalation study while part B is dose expansion study. The purpose of the dose
escalation part is to identify the maximum tolerated dose (MTD) and/or recommended phase II
dose (RP2D) of CM082 combined with paclitaxel in patients with advanced gastric cancer who
did not respond to first-line standard chemotherapy. In the subsequent dose expansion part,
additional subjects will be enrolled to further explore the safety and preliminary clinical
activity of CM082 and paclitaxel.